聞泰科技(600745.SH):擬發行可轉債募資額由不超90億元調至不超86億元
格隆匯 3 月 23日丨聞泰科技(600745.SH)公佈,為推進此次公開發行可轉換公司債券工作的順利進行,結合公司實際情況並根據公司2020年第六次臨時股東大會的授權,公司於2021年3月22日召開第十屆董事會第三十六次會議,審議通過了《關於調整公司公開發行可轉換公司債券方案的議案》、《關於公司公開發行可轉換公司債券預案(修訂稿)的議案》等相關議案。
其中,發行規模調整,擬發行可轉換公司債券募集資金總額不超過人民幣90億元(含90億元)調整至不超過人民幣86億元(含86億元),具體發行數額提請公司股東大會授權公司董事會(或由董事會授權人士)在上述額度範圍內確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.